Alto Neuroscience (ANRO) closed at $27.80 on November 9, 2026, up 10.5% from the previous close, on volume of 788,266 shares (30-day average 579,052).
Data as of November 9, 2026.
Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08
Business Wire (Wed, 4-Nov 6:57 AM ET)
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
Business Wire (Tue, 3-Nov 8:03 AM ET)
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
Business Wire (Thu, 27-Aug 4:05 PM ET)
Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Business Wire (Wed, 12-Aug 4:03 PM ET)
ANRO’s $50 Million Financing Signals Aggressive Push in Treatment-Resistant Depression Research
Market Chameleon (Mon, 20-Oct 6:29 AM ET)
Alto Neuroscience Secures $50 Million to Fast-Track Key Depression Drug: Here’s What Stands Out
Market Chameleon (Mon, 20-Oct 3:54 AM ET)
Market Chameleon (Fri, 3-Oct 6:29 AM ET)
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Alto Neuroscience trades on the NYSE stock market under the symbol ANRO.
As of November 10, 2026, ANRO stock price was flat at $27.80 with 9,434 million shares trading.
ANRO has a beta of 0.45, meaning it tends to be less sensitive to market movements. ANRO has a correlation of 0.01 to the broad based SPY ETF.
ANRO has a market cap of $1.09 billion. This is considered a Small Cap stock.
The top ETF exchange traded funds that ANRO belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.
ANRO has outperformed the market in the last year with a price return of +140.7% while the SPY ETF gained +12.6%. However, in the short term, ANRO had mixed performance relative to the market. It has underperformed in the last 3 months, returning -3.0% vs -3.0% return in SPY. But in the last 2 weeks, ANRO shares have fared better than the market returning +25.7% compared to SPY -2.2%.
ANRO support price is $26.37 and resistance is $29.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANRO shares will trade within this expected range on the day.
